VRDN
Viridian Therapeutics, Inc. Common Stock
stockNASDAQ
miragen therapeutics, inc., (nasdaq: mgen), is a biopharmaceutical company discovering and developing innovative microrna (mirna)-targeting therapies to improve human health, specifically in disease areas of high unmet medical need. the company leverages in-house expertise in mirna biology, oligonucleotide chemistry, and drug development to evaluate and advance best-in-class technologies and high-potential drug candidates for its own pipeline or in conjunction with strategic partners. at miragen, we recognize the importance of creating strategic relationships within the biotech and pharmaceutical industries and with academic institutions globally. this collaborative approach is making important contributions in our efforts to create mirna-targeting therapies. miragen's areas of focus include hematological malignancies, pathological fibrosis, neuro-degeneration, and cardiovascular disease. in 2011, the company formed a strategic partnership with servier, a privately-run, french research
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 20.57 | 2026-09-28 | -7.00% | 1.421 |
| 1M | 22.92 | 2026-09-04 | -16.54% | -1.121 |
| 3M | 18.99 | 2026-07-06 | +0.74% | 0.126 |
| 6M | 13.90 | 2026-04-06 | +37.63% | 0.797 |
| 1Y | 20.83 | 2025-10-06 | -8.16% | 0.990 |
| 2Y | 23.92 | 2024-10-04 | -20.02% | — |
| 5Y | 17.52 | 2021-10-05 | +9.19% | 0.952 |
Viridian Therapeutics, Inc. Common Stock (NASDAQ:VRDN) stock price today is $19.13, and today's volume is 1,125,838. VRDN is down 1.392% today. The 30 day average volume is 1.55M. VRDN market cap is $2.17B with 113.29M shares outstanding.